Sipagladenant (Compound I) 是一种具有口服活性的adenosine receptor A2A反向激动剂，可用于额叶功能紊乱的研究。
| 生物活性 | Sipagladenant (Compound I) is an orally activeadenosine receptorA2Ainverse agonist[1]. Sipagladenant can be used in frontal lobe dysfunction research[2]. |
体内研究
(In Vivo) | Sipagladenant (oral administration; 0.3 mg/kg; once) treatment improves cognitive impairment due to a decline in dopamine function in the medial prefrontal cortex[2].
Sipagladenant (oral administration; 0.1 mg/kg; once) treatment can improve alternation behavior[2].
Sipagladenant (oral administration; 0.1 mg/kg; once) treatment can improve gait parameters[2].
| Animal Model: | Medial prefrontal dopaminerjic terminal-lesioned CD(SD) IGS male rat[2] | | Dosage: | 0.3 mg/kg | | Administration: | Oral administration; 0.3 mg/kg; once | | Result: | Showed longer exploration time of the novel object (65.03%) than that of the familiar object (34.97%) (p<0.001). |
| Animal Model: | ICR mice with cognitive impairment and/or movement disoder[2] | | Dosage: | 0.1 mg/kg | | Administration: | Oral administration; 0.1 mg/kg; once | | Result: | Showed a significantly high alternation behavior (69.5%) as compared to the vehicle administration group (59.6%) (p<0.01). |
| Animal Model: | ICR mice with cognitive impairment and/or movement disoder[2] | | Dosage: | 0.1 mg/kg | | Administration: | Oral administration; 0.1 mg/kg; once | | Result: | Showed a significantly large maximum contact area and gait area of the left hindpaw as compared to the vehicle administration group (p<0.05), tendency of the maximum contact area and gait area of the right forepaw being large (p<0.1). |
|
| 分子量 | |
| Formula | |
| CAS 号 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
m.cnreagent.com